Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects

Wayne Tworetzky, Phillip Moore, Janine M. Bekker, James Bristow, Stephen M. Black, Jeffrey R. Fineman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVE: To determine the effect of pulmonary blood flow (Qp) on nitric oxide (NO) production in patients with increased Qp due to an atrial septal defect (ASD). BACKGROUND: Alterations in pulmonary vascular NO production have been implicated in the development of pulmonary hypertension secondary to increased Qp. In vitro, acute changes in flow or shear stress alter NO production. However, the effect of Qp on lung NO production in vivo is unclear. METHODS: Nineteen patients (2.4-61 years of age, median 17) with secundum ASD undergoing device closure were studied. Before, and 30 min after ASD closure, exhaled NO and plasma nitrate concentration were measured by chemiluminescence (NOA 280, Sievers, Boulder, Colorado). RESULTS: Before ASD closure, all patients had increased Qp (Qp: systemic blood flow [Qs] of 2.0 ± 0.7) and normal mean pulmonary arterial pressure (13.4 ± 3.1 mm Hg). Atrial septal defect device closure decreased Qp from 6.0 ± 2.5 to 3.6 ± 1.3 L/min/m2 (p < 0.05). Mean pulmonary arterial pressure was unchanged. Associated with the decrease in Qp, both exhaled NO (-22.1%, p < 0.05) and plasma nitrate concentrations (-17.9%, p < 0.05) decreased. CONCLUSIONS: These data represent the first demonstration that acute changes in Qp alter pulmonary NO production in vivo in humans. Exhaled NO determinations may provide a noninvasive assessment of pulmonary vascular NO production in patients with congenital heart disease. Potential correlations between exhaled NO, pulmonary vascular reactivity and pulmonary hypertension warrant further study. (C) 2000 by the American College of Cardiology.

Original languageEnglish (US)
Pages (from-to)463-467
Number of pages5
JournalJournal of the American College of Cardiology
Volume35
Issue number2
DOIs
StatePublished - Mar 13 2000

Fingerprint

Atrial Heart Septal Defects
Nitric Oxide
Equipment and Supplies
Lung
Blood Vessels
Pulmonary Hypertension
Nitrates
Arterial Pressure
Luminescence
Heart Diseases

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects. / Tworetzky, Wayne; Moore, Phillip; Bekker, Janine M.; Bristow, James; Black, Stephen M.; Fineman, Jeffrey R.

In: Journal of the American College of Cardiology, Vol. 35, No. 2, 13.03.2000, p. 463-467.

Research output: Contribution to journalArticle

Tworetzky, Wayne ; Moore, Phillip ; Bekker, Janine M. ; Bristow, James ; Black, Stephen M. ; Fineman, Jeffrey R. / Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects. In: Journal of the American College of Cardiology. 2000 ; Vol. 35, No. 2. pp. 463-467.
@article{334dde2aae7d4362bab1c58ff53779ee,
title = "Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects",
abstract = "OBJECTIVE: To determine the effect of pulmonary blood flow (Qp) on nitric oxide (NO) production in patients with increased Qp due to an atrial septal defect (ASD). BACKGROUND: Alterations in pulmonary vascular NO production have been implicated in the development of pulmonary hypertension secondary to increased Qp. In vitro, acute changes in flow or shear stress alter NO production. However, the effect of Qp on lung NO production in vivo is unclear. METHODS: Nineteen patients (2.4-61 years of age, median 17) with secundum ASD undergoing device closure were studied. Before, and 30 min after ASD closure, exhaled NO and plasma nitrate concentration were measured by chemiluminescence (NOA 280, Sievers, Boulder, Colorado). RESULTS: Before ASD closure, all patients had increased Qp (Qp: systemic blood flow [Qs] of 2.0 ± 0.7) and normal mean pulmonary arterial pressure (13.4 ± 3.1 mm Hg). Atrial septal defect device closure decreased Qp from 6.0 ± 2.5 to 3.6 ± 1.3 L/min/m2 (p < 0.05). Mean pulmonary arterial pressure was unchanged. Associated with the decrease in Qp, both exhaled NO (-22.1{\%}, p < 0.05) and plasma nitrate concentrations (-17.9{\%}, p < 0.05) decreased. CONCLUSIONS: These data represent the first demonstration that acute changes in Qp alter pulmonary NO production in vivo in humans. Exhaled NO determinations may provide a noninvasive assessment of pulmonary vascular NO production in patients with congenital heart disease. Potential correlations between exhaled NO, pulmonary vascular reactivity and pulmonary hypertension warrant further study. (C) 2000 by the American College of Cardiology.",
author = "Wayne Tworetzky and Phillip Moore and Bekker, {Janine M.} and James Bristow and Black, {Stephen M.} and Fineman, {Jeffrey R.}",
year = "2000",
month = "3",
day = "13",
doi = "10.1016/S0735-1097(99)00576-8",
language = "English (US)",
volume = "35",
pages = "463--467",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects

AU - Tworetzky, Wayne

AU - Moore, Phillip

AU - Bekker, Janine M.

AU - Bristow, James

AU - Black, Stephen M.

AU - Fineman, Jeffrey R.

PY - 2000/3/13

Y1 - 2000/3/13

N2 - OBJECTIVE: To determine the effect of pulmonary blood flow (Qp) on nitric oxide (NO) production in patients with increased Qp due to an atrial septal defect (ASD). BACKGROUND: Alterations in pulmonary vascular NO production have been implicated in the development of pulmonary hypertension secondary to increased Qp. In vitro, acute changes in flow or shear stress alter NO production. However, the effect of Qp on lung NO production in vivo is unclear. METHODS: Nineteen patients (2.4-61 years of age, median 17) with secundum ASD undergoing device closure were studied. Before, and 30 min after ASD closure, exhaled NO and plasma nitrate concentration were measured by chemiluminescence (NOA 280, Sievers, Boulder, Colorado). RESULTS: Before ASD closure, all patients had increased Qp (Qp: systemic blood flow [Qs] of 2.0 ± 0.7) and normal mean pulmonary arterial pressure (13.4 ± 3.1 mm Hg). Atrial septal defect device closure decreased Qp from 6.0 ± 2.5 to 3.6 ± 1.3 L/min/m2 (p < 0.05). Mean pulmonary arterial pressure was unchanged. Associated with the decrease in Qp, both exhaled NO (-22.1%, p < 0.05) and plasma nitrate concentrations (-17.9%, p < 0.05) decreased. CONCLUSIONS: These data represent the first demonstration that acute changes in Qp alter pulmonary NO production in vivo in humans. Exhaled NO determinations may provide a noninvasive assessment of pulmonary vascular NO production in patients with congenital heart disease. Potential correlations between exhaled NO, pulmonary vascular reactivity and pulmonary hypertension warrant further study. (C) 2000 by the American College of Cardiology.

AB - OBJECTIVE: To determine the effect of pulmonary blood flow (Qp) on nitric oxide (NO) production in patients with increased Qp due to an atrial septal defect (ASD). BACKGROUND: Alterations in pulmonary vascular NO production have been implicated in the development of pulmonary hypertension secondary to increased Qp. In vitro, acute changes in flow or shear stress alter NO production. However, the effect of Qp on lung NO production in vivo is unclear. METHODS: Nineteen patients (2.4-61 years of age, median 17) with secundum ASD undergoing device closure were studied. Before, and 30 min after ASD closure, exhaled NO and plasma nitrate concentration were measured by chemiluminescence (NOA 280, Sievers, Boulder, Colorado). RESULTS: Before ASD closure, all patients had increased Qp (Qp: systemic blood flow [Qs] of 2.0 ± 0.7) and normal mean pulmonary arterial pressure (13.4 ± 3.1 mm Hg). Atrial septal defect device closure decreased Qp from 6.0 ± 2.5 to 3.6 ± 1.3 L/min/m2 (p < 0.05). Mean pulmonary arterial pressure was unchanged. Associated with the decrease in Qp, both exhaled NO (-22.1%, p < 0.05) and plasma nitrate concentrations (-17.9%, p < 0.05) decreased. CONCLUSIONS: These data represent the first demonstration that acute changes in Qp alter pulmonary NO production in vivo in humans. Exhaled NO determinations may provide a noninvasive assessment of pulmonary vascular NO production in patients with congenital heart disease. Potential correlations between exhaled NO, pulmonary vascular reactivity and pulmonary hypertension warrant further study. (C) 2000 by the American College of Cardiology.

UR - http://www.scopus.com/inward/record.url?scp=0034048932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034048932&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(99)00576-8

DO - 10.1016/S0735-1097(99)00576-8

M3 - Article

C2 - 10676695

AN - SCOPUS:0034048932

VL - 35

SP - 463

EP - 467

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -